These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30460842)

  • 1. Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.
    Elsayed MSA; Nielsen JJ; Park S; Park J; Liu Q; Kim CH; Pommier Y; Agama K; Low PS; Cushman M
    J Med Chem; 2018 Dec; 61(23):10440-10462. PubMed ID: 30460842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
    Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
    Hamaguchi H; Amano Y; Moritomo A; Shirakami S; Nakajima Y; Nakai K; Nomura N; Ito M; Higashi Y; Inoue T
    Bioorg Med Chem; 2018 Oct; 26(18):4971-4983. PubMed ID: 30145050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
    Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R
    J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors.
    Kim W; Lee SM; Jeong PH; Jung JH; Kim YC
    Bioorg Med Chem Lett; 2022 Jan; 55():128451. PubMed ID: 34774741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
    McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
    Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure-activity relationship.
    Pal R; Matada GSP; Teli G; Saha M; Patel R
    Bioorg Chem; 2024 Nov; 152():107696. PubMed ID: 39167870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
    Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
    Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.
    Wang Y; Huang W; Xin M; Chen P; Gui L; Zhao X; Zhu X; Luo H; Cong X; Wang J; Liu F
    Bioorg Med Chem; 2019 Jun; 27(12):2592-2597. PubMed ID: 30926315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delgocitinib: First Approval.
    Dhillon S
    Drugs; 2020 Apr; 80(6):609-615. PubMed ID: 32166597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
    Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
    Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on JAK Inhibitors.
    Musumeci F; Greco C; Giacchello I; Fallacara AL; Ibrahim MM; Grossi G; Brullo C; Schenone S
    Curr Med Chem; 2019; 26(10):1806-1832. PubMed ID: 29589523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of janus kinase inhibitors in the treatment of alopecia areata.
    Triyangkulsri K; Suchonwanit P
    Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
    Flanagan ME; Blumenkopf TA; Brissette WH; Brown MF; Casavant JM; Shang-Poa C; Doty JL; Elliott EA; Fisher MB; Hines M; Kent C; Kudlacz EM; Lillie BM; Magnuson KS; McCurdy SP; Munchhof MJ; Perry BD; Sawyer PS; Strelevitz TJ; Subramanyam C; Sun J; Whipple DA; Changelian PS
    J Med Chem; 2010 Dec; 53(24):8468-84. PubMed ID: 21105711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.
    Xiang J; Wang Y; Wang W; Yu J; Zheng L; Hong Y; Shi L; Zhang C; Chen N; Xu J; Gong X; Zhang Z; Cui H; Zhou Q; Zhang D; Liu Y; Ke Y; Shen J; Xia G; Bai X
    Bioorg Chem; 2023 Nov; 140():106765. PubMed ID: 37582330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
    Wei X; Wu J; Zhao G; Galdamez J; Lele SM; Wang X; Liu Y; Soni DM; Purdue PE; Mikuls TR; Goldring SR; Wang D
    Mol Pharm; 2018 Aug; 15(8):3456-3467. PubMed ID: 29966420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
    Norman P
    Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of hydrazinyl-containing pyrrolo[2,3-d]pyrimidine series as potent, selective and oral JAK1 inhibitors for the treatment of rheumatoid arthritis.
    Mao W; Wu H; Guo Q; Zheng X; Wei C; Liao Y; Shen L; Mi J; Li J; Chen S; Qian W
    Bioorg Med Chem Lett; 2022 Oct; 74():128905. PubMed ID: 35870730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.